Skip to main content
SpringerLink
Log in

Comparison of Tissue and Blood Concentrations of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new technology for delivering intraperitoneal chemotherapy. It is generally assumed that with PIPAC, the ratio of peritoneal to systemic drug concentration is superior to liquid hyperthermic intraperitoneal chemotherapy (HIPEC). To date, no direct comparative data are available supporting such an assumption.

Materials and Methods

Twelve 65-day-old pigs were randomly separated into three groups of four pigs each, all of which received intraperitoneal chemotherapy using the following administration methods: PIPAC with oxaliplatin 92 mg in 150 ml dextrose 5% (Group 1); PIPAC with electrostatic aerosol precipitation (ePIPAC; Group 2); or laparoscopic HIPEC (L-HIPEC) with oxaliplatin 400 mg in 4 L dextrose 5% at 42 °C (Group 3). Serial blood and peritoneal tissue concentrations of oxaliplatin were determined by spectrometry.

Results

In all three groups, the maximum concentration of oxaliplatin in blood was detected 50–60 min after onset of the chemotherapy experiments, with no significant differences among the three groups (p = 0.7994). Blood oxaliplatin concentrations (0–30 min) were significantly higher in the L-HIPEC group compared with the ePIPAC group (p < 0.05). No difference was found for the overall systemic oxaliplatin absorption (area under the curve). Overall concentrations in the peritoneum were not different among the three groups (p = 0.4725), but were significantly higher in the visceral peritoneum in the PIPAC group (p = 0.0242).

Conclusions

Blood and tissue concentrations were comparable between all groups; however, depending on the intraperitoneal area examined and the time points of drug delivery, the concentrations differed significantly between the three groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Goodman MD, McPartland S, Detelich D, et al. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7:45–57.

    Article  Google Scholar 

  2. Garofalo A, Valle M, Garcia J, et al. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol. 2006;32:682–5.

    Article  CAS  Google Scholar 

  3. Facchiano E, Scaringi S, Kianmanesh R, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol. 2008;34:154–8.

    Article  CAS  Google Scholar 

  4. Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol. 2009;15:331–4.

    Article  Google Scholar 

  5. Ba MC, Van der Speeten K, Garofalo A. Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol. 2010;16:1901–7.

    Article  CAS  Google Scholar 

  6. Ba MC, Long H, Zhang XL, et al. Laparoscopic hyperthermic intraperitoneal perfusion chemotherapy for patients with malignant ascites secondary to unresectable gastric cancer. J Laparoendosc Adv Surg Tech. 2016;26:32–9.

    Article  Google Scholar 

  7. Solaß W, Hetzel A, Nadiradze G, et al. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26:849–1855.

    Google Scholar 

  8. Solaß W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 2014;21:553–559.

    Article  Google Scholar 

  9. Kakchekeeva T, Demtröder C, Herath NI, et al. In vivo feasibility of electrostatic precipitation as an adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). Ann Surg Oncol. 2016;23:592–598.

    Article  Google Scholar 

  10. Giger-Pabst U, Tempfer CB. How to perform safe and technically optimized pressurized intraperitoneal aerosol chemotherapy (PIPAC): experience after a consecutive series of 1200 procedures. J Gastrointest Surg. 2018;22:2187–2193.

    Article  Google Scholar 

  11. Ferron G, Gesson-Paute A, Classe JM, et al. Feasibility of laparoscopic peritonectomy followed by intra-peritoneal chemohyperthermia: an experimental study. Gynecol Oncol. 2005;99:358–61.

    Article  Google Scholar 

  12. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49–58.

    Google Scholar 

  13. Murono K, Kawai K, Hata K, et al. Regimens of intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Anticancer Res. 2018;38:15–22.

    CAS  PubMed  Google Scholar 

  14. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89:480–487.

    Article  CAS  Google Scholar 

  15. Solaß W, Hetzel A, Nadiradze G, et al. Intraoperative intraperitoneal drug delivery using a nebulizer: rationale and pharmacokinetic results. Surg Endosc. 2012;26:1849–1855.

    Article  Google Scholar 

  16. Solass W, Herbette A, Schwarz T, et al. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc. 2012;52:847–52.

    Article  Google Scholar 

  17. Demtröder C, Solass W, Zieren J, Strumber D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis. 2016;18: 364–371.

    Article  Google Scholar 

  18. Schilling MK, Redaelli C, Krahenbuhl L, et al. Splanchnic microcirculatory changes during CO2 laparoscopy. J Am Coll Surg. 1997;184:378–382.

    CAS  PubMed  Google Scholar 

  19. Blanco A, Giger-Pabst U, Solass W, et al. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013;20:2311–2316.

    Article  Google Scholar 

  20. Göhler D, Khosrawipour V, Khosrawipour T, et al. Technical description of the microinjection pump (MIP®) and granulometric characterization of the aerosol applied for pressurized intraperitoneal aerosol chemotherapy (PIPAC). Surg Endosc. 2017;31:1778–1784.

    Article  Google Scholar 

  21. Bellendorf A, Khosrawipour V, Khosrawipour T, et al. Scintigraphic peritoneography reveals a non-uniform 99mTc-Pertechnetat aerosol distribution pattern for pressurized intra-peritoneal aerosol chemotherapy (PIPAC) in a swine model. Surg Endosc. 2018;32:166–174.

    Article  Google Scholar 

  22. Göhler D, Große S, Bellendorf A, et al. Hyperthermic intracavitary nanoaerosol therapy (HINAT) as an improved approach for pressurized intraperitoneal aerosol chemotherapy (PIPAC): Technical description, experimental validation and first proof of concept. Beilstein J Nanotechnol. 2017;18:2729–2740.

    Article  Google Scholar 

Download references

Acknowledgment

The authors are thankful to the staff of the CIRS Department at INRA Centre, Val de Loire, France, for their important support in performing the animal experiments. The authors are also deeply thankful to Julien Sobilo at CIPA-TAAM, CNRS Orleans, for data processing, and Katarzyna Gaj for her important secretarial assistance.

Funding

This study was funded by institutional funds.

Author information

Authors and Affiliations

  1. Department of General, Visceral and Transplant Surgery, University of Münster, Münster, Germany

    Urs Giger-Pabst MD & Cédric Demtröder MD

  2. Department of General Surgery, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany

    Urs Giger-Pabst MD, Thomas Albert Falkenstein MD & Cédric Demtröder MD

  3. Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray Les Tours, France

    Petru Bucur MD, PhD, Nicolas Tabchouri MD, Ephrem Salamé MD, PhD & Mehdi Ouaissi MD, PhD

  4. EA4245 Transplantation Immunologie Inflammation, Université de Tours, Tours, France

    Sébastien Roger PhD & Mehdi Ouaissi MD, PhD

  5. CNRS UPS44, CIPA, PHENOMIN-TAAM, Orléans, France

    Alain Le Pape PhD & Stéphanie Lerondel PhD

Authors
  1. Urs Giger-Pabst MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Petru Bucur MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sébastien Roger PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Albert Falkenstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicolas Tabchouri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alain Le Pape PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stéphanie Lerondel PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Cédric Demtröder MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ephrem Salamé MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mehdi Ouaissi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

UG-P: Study design, animal experiments, data acquisition, data interpretation, manuscript drafting, and critical revision for important intellectual content of the manuscript. PB, ALP: Study design, study protocol, and critical revision for important intellectual content of the manuscript. SR, ALP, SL: Critical revision for important intellectual content of the manuscript. TAF: Animal experiments and data acquisition. NT: Data analysis and interpretation. CD: Critical revision for important intellectual content of the manuscript. ES: Critical revision for important intellectual content of the manuscript. MO: Study design, study protocol, animal experiments, data acquisition, data interpretation, manuscript drafting, and critical revision for important intellectual content of the manuscript.

Corresponding author

Correspondence to Mehdi Ouaissi MD, PhD.

Ethics declarations

Disclosure

Urs Giger-Pabst, Petru Bucur, Sébastien Roger, Thomas Albert Falkenstein, Nicolas Tabchouri, Alain Le Pape, Stéphanie Lerondel, Cédric Demtröder, Ephrem Salamé, and Mehdi Ouaissi have no conflicts of interest to declare.

Availability of Data and Materials

The dataset of the current study is available from the corresponding author upon reasonable request.

Ethical Approval

The study protocol was approved by the local Animal Ethics Committee, Val de Loire, France.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giger-Pabst, U., Bucur, P., Roger, S. et al. Comparison of Tissue and Blood Concentrations of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy. Ann Surg Oncol 26, 4445–4451 (2019). https://doi.org/10.1245/s10434-019-07695-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-07695-z

Search

Navigation